Diabetes and Bone Fragility

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2020 Nov 13

PMID 33185853

Citations 32

Authors

Camila Romero-Diaz

Daniela Duarte-Montero

Sebastian A Gutierrez-Romero

Carlos O Mendivil

Affiliations

Soon will be listed here.

Abstract

Diabetes is a highly prevalent disease with complications that impact most bodily systems. However, the impact of diabetes on bone health is frequently ignored or underestimated. Both type 1 (T1D) and type 2 diabetes (T2D) are associated with a higher risk of fractures, albeit through different mechanisms. T1D is characterized by near total insulinopenia, which affects the anabolic tone of bone and results in reduced bone mineral density (BMD). Meanwhile, patients with T2D have normal or high BMD, but carry an increased risk of fractures due to alterations of bone microarchitecture and a local humoral environment that stimulates osteoclast activity. Chronic hyperglycemia induces non-enzymatic glycation of collagen in both types of diabetes. Epidemiological evidence confirms a largely increased fracture risk in T1D and T2D, but also that it can be substantially reduced by opportune monitoring of fracture risk and appropriate treatment of both diabetes itself and osteopenia or osteoporosis if they are present. In this review, we summarize the mechanistic, epidemiological, and clinical evidence that links diabetes and bone fragility, and describe the impact of available diabetes treatments on bone health.

Citing Articles

The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.

Zhong S, Huang L, Lin T, Li Y, Deng B, Kong D Iran J Pharm Res. 2025; 23(1):e148139.

PMID: 40066121 PMC: 11892751. DOI: 10.5812/ijpr-148139.

Burden of rheumatic diseases among people with diabetes: A systematic review and meta-analysis.

Mamadapur M, Gaidhane A, Padhi B, Zahiruddin Q, Sharma R, Rustagi S Narra J. 2025; 4(3):e863.

PMID: 39816121 PMC: 11731666. DOI: 10.52225/narra.v4i3.863.

Association between diabetes mellitus and trochanteric bone mineral density in individuals with osteoporotic fractures: a retrospective study.

Guo S, Xu J, Xu M, Li C, Gong Y, Lu K Front Med (Lausanne). 2025; 11:1492603.

PMID: 39741509 PMC: 11685145. DOI: 10.3389/fmed.2024.1492603.

Understanding the impact of diabetes on bone health: A clinical review.

Sharma P, Sharma R, Gaur K Metabol Open. 2024; 24:100330.

PMID: 39606009 PMC: 11600011. DOI: 10.1016/j.metop.2024.100330.

Fracture severity dependence of bone and muscle performance in patients following single or multiple vertebral fractures.

Zhang C, Li Y, Wang G, Sun J Front Endocrinol (Lausanne). 2024; 15:1423650.

PMID: 39568809 PMC: 11576194. DOI: 10.3389/fendo.2024.1423650.

References

Napoli N, Chandran M, Pierroz D, Abrahamsen B, Schwartz A, Ferrari S . Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2016; 13(4):208-219. DOI: 10.1038/nrendo.2016.153. View

Vestergaard P, Rejnmark L, Mosekilde L . Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2008; 84(1):45-55. DOI: 10.1007/s00223-008-9195-5. View

Bischoff-Ferrari H, Dawson-Hughes B, Staehelin H, Orav J, Stuck A, Theiler R . Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339:b3692. PMC: 2755728. DOI: 10.1136/bmj.b3692. View

Humphers J, Shibuya N, Fluhman B, Jupiter D . The impact of glycosylated hemoglobin and diabetes mellitus on wound-healing complications and infection after foot and ankle surgery. J Am Podiatr Med Assoc. 2014; 104(4):320-9. DOI: 10.7547/0003-0538-104.4.320. View

Janghorbani M, van Dam R, Willett W, Hu F . Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5):495-505. DOI: 10.1093/aje/kwm106. View

Anagnostis P, Paschou S, Gkekas N, Artzouchaltzi A, Christou K, Stogiannou D . Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review. Endocrine. 2018; 60(3):373-383. DOI: 10.1007/s12020-018-1548-x. View

Ivers R, Cumming R, Mitchell P, Peduto A . Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001; 24(7):1198-203. DOI: 10.2337/diacare.24.7.1198. View

Paschou S, Dede A, Anagnostis P, Vryonidou A, Morganstein D, Goulis D . Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10):3621-3634. DOI: 10.1210/jc.2017-00042. View

McCarthy A, Etcheverry S, Bruzzone L, Lettieri G, Barrio D, Cortizo A . Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001; 2:16. PMC: 37548. DOI: 10.1186/1471-2121-2-16. View

10.

Watts N, Bilezikian J, Usiskin K, Edwards R, Desai M, Law G . Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2015; 101(1):157-66. PMC: 4701850. DOI: 10.1210/jc.2015-3167. View

11.

Uchida T, Nakamura T, Hashimoto N, Matsuda T, Kotani K, Sakaue H . Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med. 2005; 11(2):175-82. DOI: 10.1038/nm1187. View

12.

Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T . Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008; 375(3):414-9. DOI: 10.1016/j.bbrc.2008.08.034. View

13.

Poundarik A, Wu P, Evis Z, Sroga G, Ural A, Rubin M . A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater. 2015; 52:120-130. PMC: 4651854. DOI: 10.1016/j.jmbbm.2015.08.012. View

14.

Trierweiler H, Kisielewicz G, Jonasson T, Petterle R, Moreira C, Borba V . Sarcopenia: a chronic complication of type 2 diabetes mellitus. Diabetol Metab Syndr. 2018; 10:25. PMC: 5883537. DOI: 10.1186/s13098-018-0326-5. View

15.

Fang X, Yu S, Eder A, Mao M, Bast Jr R, Boyd D . Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999; 18(48):6635-40. DOI: 10.1038/sj.onc.1203076. View

16.

Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer L, Chines A . Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone. 2020; 134:115268. DOI: 10.1016/j.bone.2020.115268. View

17.

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

18.

Mieczkowska A, Mansur S, Irwin N, Flatt P, Chappard D, Mabilleau G . Alteration of the bone tissue material properties in type 1 diabetes mellitus: A Fourier transform infrared microspectroscopy study. Bone. 2015; 76:31-9. DOI: 10.1016/j.bone.2015.03.010. View

19.

Nuti R, Martini G, Valenti R, Gambera D, Gennari L, Salvadori S . Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res. 2004; (422):208-13. DOI: 10.1097/01.blo.0000129163.97988.06. View

20.

Zhao C, Liu G, Zhang Y, Xu G, Yi X, Liang J . Association between serum levels of bone turnover markers and bone mineral density in men and women with type 2 diabetes mellitus. J Clin Lab Anal. 2019; 34(4):e23112. PMC: 7171297. DOI: 10.1002/jcla.23112. View